Advances in Treatment of Substance Use Disorders (SUDs)
A special issue of Healthcare (ISSN 2227-9032). This special issue belongs to the section "Medication Management".
Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 1831
Special Issue Editor
Interests: stress reactivity; psychosocial stress; premenstrual syndrome; premenstrual dysphoric disorder; smoking cessation; tobacco use disorder; neuroactive steroid hormones; heart rate variability; genetic association analysis; intranasal insulin; substance use disorders; impulsivity; cognition; amphetamine
Special Issue Information
Dear Colleagues,
Substance use disorders are the leading cause of disability worldwide. This major public health issue impacts patients, caregivers, families, and communities across the world. The lack of successful treatments is related to the limited neurobiological targeting of the currently approved substance use disorder treatments, poorly identified mechanistic and clinical outcome markers, and inadequate integration of treatment approaches for comorbid substance use disorders and mental illnesses.
The articles in this Special Issue of Healthcare feature an international collection of professional contributions related to developments in novel pharmacologic and non-pharmacologic substance use disorder interventions. The goal is to publish studies that test clinical trial safety and efficacy, describe the results of basic experimental animal/human research, or evaluate epidemiologic data. Additional, and equally important, consideration will be given to studies that examine mechanisms of behavioral change, determine treatment optimization, and ascertain the best sequencing of behavioral, combined, or integrated behavioral and pharmacological treatments.
The Special Issue encourages research applications to support a diverse array of articles, including original research manuscripts, reviews, and case reports.
Dr. Ajna Hamidovic
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Healthcare is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug addiction
- opioids
- nicotine
- smoking
- alcohol
- amphetamines
- cocaine
- cannabis
- sedatives
- hypnotics
- benzodiazepines
- stimulants
